menu

Treatment HBV and HDV infection

Myrcludex B

MYR GmbH is focused on development of Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection.

Treatment HBV and HDV infection

Myrcludex B

MYR GmbH is focused on development of Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection.

Treatment HBV and HDV infection

Myrcludex B

MYR GmbH is focused on development of Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection.

Welcome to the Myr GmbH company's website

features

MYR GmbH is focused on development of Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection. Myrcludex B inhibits the essential HBV receptor and prevents spread of HBV in the liver. HDV is using HBV envelope to infect liver cells and may be targeted by Myrcludex B either. The product has a landscape-changing potential in both indications.

More information

If you want to collaborate and research with Myr GmbH please contact

In addition to the license agreement, MYR has a collaboration and research agreement with the University Hospital Heidelberg!

Contact us!

latest news

Our team

Graduated in human medicine.15+ years in drug development: Senior research positions with Pharma and Biotech: Fresenius AG, Vision7 GmbH, Biontech AG.

Dr. Alexander Alexandrov

Dr. Alexander Alexandrov

CEO/CMO

Graduated in economy. CFO of Kaufhof, Continental Group companies. Since 1999 business angel and CFO of Biotech companies.

Dr. Jörn Möller

Dr. Jörn Möller

CFO

our investors and partners